SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-066282
Filing Date
2022-03-04
Accepted
2022-03-04 17:04:37
Documents
17
Period of Report
2022-02-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d291963d8k.htm   iXBRL 8-K 32301
2 EX-10.1 d291963dex101.htm EX-10.1 5202
3 EX-10.2 d291963dex102.htm EX-10.2 50321
4 EX-10.3 d291963dex103.htm EX-10.3 7148
8 GRAPHIC g291963snap005.jpg GRAPHIC 1747
9 GRAPHIC g291963sp5.jpg GRAPHIC 3629
  Complete submission text file 0001193125-22-066282.txt   246598

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ctic-20220228.xsd EX-101.SCH 2872
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20220228_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20220228_pre.xml EX-101.PRE 11272
11 EXTRACTED XBRL INSTANCE DOCUMENT d291963d8k_htm.xml XML 3434
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 22715093
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences